Preliminary Communication

Identification of novel genes by whole-exome sequencing can improve gastric cancer precision oncology

Georgios D Lianos

Centre for Biosystems & Genomic Network Medicine, University of Ioannina, Ioannina, Greece

Department of Surgery, School of Medicine, University of Ioannina, Ioannina, Greece

Search for more papers by this author

Georgios K Glantzounis

Department of Surgery, School of Medicine, University of Ioannina, Ioannina, Greece

Search for more papers by this author

Christina D Bali

Department of Surgery, School of Medicine, University of Ioannina, Ioannina, Greece

Search for more papers by this author

Christos Katsios

Centre for Biosystems & Genomic Network Medicine, University of Ioannina, Ioannina, Greece

Department of Surgery, School of Medicine, University of Ioannina, Ioannina, Greece

Search for more papers by this author

Dimitrios H Roukos

*Author for correspondence:

E-mail Address: droukos@uoi.gr

Centre for Biosystems & Genomic Network Medicine, University of Ioannina, Ioannina, Greece

Department of Surgery, School of Medicine, University of Ioannina, Ioannina, Greece

Commision of Innovation & Research, University of Ioannina, Ioannina, Greece

Biomedical Research Foundation of the Academy of Athens (BRFAA), Systems Biology, Athens, Greece

Search for more papers by this author

Published Online:29 Nov 2016https://doi.org/10.2217/fon-2016-0430

View article

Abstract

Aim: By identifying cancer driver genes involved in tumorigenesis, whole-exome sequencing (WES) analyses enable the development of robust biomarkers and novel therapeutic targets to reach precision oncology. Patients & methods: WES analyses were performed in matched gastric cancer-normal gastric tissues from two patients. We compared genes highlighted with those of a database and recent WES/whole-genome sequencing studies. Results: We identified 32 highlighted gastric cancer genes, two of these (DEFB118 and RNF43) may provide future potential clinical implications. Conclusion: Definitive evidence on extensive genetic heterogeneity suggests the need for large-scale next-generation sequencing studies to validate gastric cancer driver genes catalog. This list represents the foundation for developing genome-based biomarkers to guide precision gastric cancer treatment.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1 Roukos DH, Ku CS. Clinical cancer genome and precision medicine. Ann. Surg. Oncol. 19(12), 3646–3650 (2012).Crossref, Medline, Google Scholar
2 Ku CS, Roukos DH. From next-generation sequencing to nanopore sequencing technology: paving the way to personalized genomic medicine. Expert Rev. Med. Devices 10(1), 1–6 (2013).Crossref, Medline, CAS, Google Scholar
3 Liu B, Conroy JM, Morrison CD et al. Structural variation discovery in the cancer genome using next generation sequencing: computational solutions and perspectives. Oncotarget 6(8), 5477–5489 (2015).Crossref, Medline, Google Scholar
4 Angrist M. Start me up: ways to encourage sharing of genomic information with research participants. Nat. Rev. Genet. 16(8), 435–436 (2015).Crossref, Medline, CAS, Google Scholar
5 ENCODE Project Consortium. Dunham I, Kundaje A, Aldred SF et al. An integrated encyclopedia of DNA elements in the human genome. Nature 489(7414), 57–74 (2012).Crossref, Medline, Google Scholar
6 Lawrence MS, Stojanov P, Mermel CH et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505(7484), 495–501 (2014). •• WES study across 21 tumor types.Crossref, Medline, CAS, Google Scholar
7 Klein CA. Selection and adaptation during metastatic cancer progression. Nature 501(7467), 365–372 (2013). •• Important study about metastatic progression.Crossref, Medline, CAS, Google Scholar
8 Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature 501(7467), 355–364 (2013). • Special focus on cancer heterogeneity.Crossref, Medline, CAS, Google Scholar
9 Roukos DH. Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann. Surg. Oncol. 17(1), 14–17 (2010).Crossref, Medline, Google Scholar
10 Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase III, open-label, randomised controlled trial. Lancet 376(9742), 687–697 (2010).Crossref, Medline, CAS, Google Scholar
11 Roukos DH. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J. 11(2), 81–92 (2011).Crossref, Medline, CAS, Google Scholar
12 Aparicio S, Caldas C. The implications of clonal genome evolution for cancer medicine. N. Engl. J. Med. 368, 842–851 (2013). • Very important study about clonal evolution.Crossref, Medline, CAS, Google Scholar
13 Lianos GD, Bali CD, Glantzounis GK, Katsios C, Roukos DH. BMI and lymph node ratio may predict clinical outcomes of gastric cancer. Future Oncol. 10(2), 249–255 (2014).Link, CAS, Google Scholar
14 Sandusky GE, Teheny KH, Esterman M et al. Quality control of human tissues – experience from the Indiana University Cancer Center-Lilly Research Labs human tissue bank. Cell Tissue Bank 8(4), 287–295 (2007).Crossref, Medline, Google Scholar
15 Guo J, Miao Y, Xiao B et al. Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J. Gastroenterol. Hepatol. 24(4), 652–657 (2009).Crossref, Medline, CAS, Google Scholar
16 Spruessel A, Steimann G, Jung M et al. Tissue ischemia time affects gene and protein expression patterns within minutes following surgical tumor excision. Biotechniques 36(6), 1030–1037 (2004).Crossref, Medline, CAS, Google Scholar
17 Wong SS, Kim KM, Ting JC et al. Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing. Nat. Commun. 5, 5477 (2014).Crossref, Medline, Google Scholar
18 Wang K, Yuen ST, Xu J et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat. Genet. 46(6), 573–582 (2014). •• Large whole-genome sequencing study about gastric cancer.Crossref, Medline, CAS, Google Scholar
19 Wang K, Kan J, Yuen ST et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat. Genet. 43, 1219–1223 (2011). • Whole-exome sequencing study highlighting heterogeneity of gastric cancer.Crossref, Medline, CAS, Google Scholar
20 Zang ZJ, Cutcutache I, Poon SL et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat. Genet. 44, 570–574 (2012). • Whole-exome sequencing study highlighting chromatin remodeling genes in gastric cancer.Crossref, Medline, CAS, Google Scholar
21 Lin Y, Wu Z, Guo W, Li J. Gene mutations in gastric cancer: a review of recent next-generation sequencing studies. Tumour Biol. 36(10), 7385–7394 (2015).Crossref, Medline, CAS, Google Scholar
22 Eirew P, Steif A, Khattra J et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 518(7539), 422–426 (2015).Crossref, Medline, CAS, Google Scholar
23 Gerstein MB, Kundaje A, Hariharan M et al. Architecture of the human regulatory network derived from ENCODE data. Nature 489(7414), 91–100 (2012). • Focuses on human regulatory network.Crossref, Medline, CAS, Google Scholar
24 Rosenfeld S. Characteristics of transcriptional activity in nonlinear dynamics of genetic regulatory networks. Gene Regul. Syst. Bio. 23, 159–179 (2009).Google Scholar
25 Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366(10), 883–892 (2012). •• Exceptional study focusing on intratumor heterogeneity.Crossref, Medline, CAS, Google Scholar
26 Murtaza M, Dawson SJ, Tsui DW et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108–112 (2013).Crossref, Medline, CAS, Google Scholar
27 Bettegowda C, Sausen M, Leary R et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6, 224ra24 (2014).Crossref, Medline, Google Scholar
28 Fox EJ, Loeb LA. Cancer: one cell at a time. Nature 512(7513), 143–144 (2014). • Very interesting editorial article about tumor heterogeneity.Crossref, Medline, CAS, Google Scholar
29 Roukos DH. Crossroad between linear and non linear trancription concepts in the discovery of next-generation sequencing systems based anticancer therapies. Drug Discov. Today 21(4), 663–673 (2016).Crossref, Medline, CAS, Google Scholar
30 US Food & Drug Administration Website (2016). www.fda.gov Crossref, Google Scholar
31 De Mattos-Arruda L et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann. Oncol. 25(9), 1729–1735 (2014).Crossref, Medline, CAS, Google Scholar

Vol. 13, No. 10

Metrics

Downloaded 197 times

History

Published online 29 November 2016

Published in print April 2017

Information

Keywords

Author contributions

GD Lianos, GK Glantzounis and DH Roukos designed the study. GD Lianos and CD Bali collected the data. GD Lianos and DH Roukos wrote the paper. GK Glantzounis, DH Roukos and C Katsios critically revised the manuscript. All authors read and approved the submitted version.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download